Renal Cell Carcinoma News
Researchers evaluated telomere length samples from 184 patients with von Hippel-Lindau syndrome to determine whether shortened telomere length can predict cancer risk.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.
Savolitinib was tolerable, safe, and may have treatment potential for patients with MET-driven papillary renal cell carcinoma.
Downregulation of apoptosis stimulating of p53 protein 1 confers drug resistance and permits tumor growth in clear cell renal cell carcinoma.
Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.
A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.
Overall, 3.5 million cells were analyzed and 17 major tumor-associated macrophage phenotypes were identified.
This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.
Study results suggest that 99mTc-MIBI SPECT/CT use can improve the differentiation between benign and malignant kidney tumors.
Two children with recurrent metastatic, TFE3 fusion-positive RCC that expressed MET experienced "prolonged disease control" following treatment with cabozantinib.
Study findings suggest that BET inhibitors might be a promising avenue of drug-development against RCC.
Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.
Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.
Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.
The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective